If you want to work with generic-medicine or pharmaceutical companies as a Clearing & Forwarding agent, the real decision is based on territory need, statutory licences, storage capability, inventory control, trained manpower, dispatch discipline, systems, reverse logistics and the exact commercial agreement.
This page is designed as a complete 2026 C&F agent operating blueprint for the generic-medicine sector in India. It explains what a pharma C&F agent actually does, how C&F differs from distributorship and PCD franchise, what licences may apply, how to plan a warehouse, how investment and earnings should be calculated, what leading companies look for, and how to verify a genuine vacancy before you spend money.
Current industry context from the Government of India / Department of Pharmaceuticals, published in 2026. These are sector figures—not a promise of C&F vacancies or returns.
1. What does a pharma C&F agent actually do?
A Clearing & Forwarding agent sits much closer to the pharmaceutical company's supply chain than a normal retail distributor. The Competition Commission of India's pharmaceutical market study describes C&F agents as, in many cases, the first channel after the manufacturer. Their functions can include storage, execution of supply orders, maintaining stockist receivables/records, reporting and market information. The exact commercial and legal responsibility, however, is controlled by the appointment agreement.
correct storage & handling
traceability & expiry control
accurate billing & dispatch
records, controls & compliance
availability without quality loss
Typical day-to-day responsibilities can include
- Receiving consignments from the principal/manufacturer and checking quantity, batch and physical condition.
- Storage according to applicable label conditions, regulatory requirements and company SOPs.
- Batch-wise inventory control, FIFO/FEFO discipline where applicable, and expiry monitoring.
- Processing orders received for authorised stockists/distributors/institutions.
- Billing/dispatch as authorised by the principal and maintaining auditable records.
- Handling returns, near-expiry stock, damaged stock, recalls and reverse logistics as per written procedure.
- Providing stock, sales, outstanding and operational reports to the company.
- Maintaining trained staff, security, fire safety, pest control, power backup and cold-chain systems where the portfolio needs them.
- Supporting audits and complying with statutory licences applicable to the premises and products handled.
2. C&F Agent vs Super Stockist vs Distributor vs PCD Franchise
This distinction is critical because many online pages mix all four models and then quote one investment or margin. The economics are fundamentally different.
| Model | Primary role | Inventory economics | Main earning logic | Biggest applicant question |
|---|---|---|---|---|
| C&F / CFA | Storage, order execution, dispatch & principal support | Often principal-owned stock, but contract decides | Service / handling / fixed / variable fee structure | What exact services and liabilities are mine? |
| Super Stockist | Large-area inventory and downstream supply | May carry purchased stock / working capital | Trade margin / scheme / territory economics | How much capital is locked in stock and credit? |
| Distributor / Stockist | Supply to retailers, hospitals or local trade | Usually inventory and receivable intensive | Trade margin + schemes minus route cost | Can the territory support profitable secondary sales? |
| PCD / Pharma Franchise | Promotion/marketing rights for selected products/territory | Commercial purchase/marketing model varies | Product margin + market development | Do I have prescriber/market-development capability? |
Veteran rule: if a proposal calls itself “C&F” but asks you to buy large opening stock, give heavy retailer credit and build retail sales yourself, read the contract carefully. The model may economically behave more like a super stockist/distributor than a pure C&F arrangement.
3. What does “generic medicine” mean in this opportunity?
In the Indian market, the term “generic medicine” is used in several ways: unbranded medicines sold by generic name, branded generics, trade generics and broad off-patent formulation portfolios. A March 2026 Government of India reply stated that there is no definition of “generic medicines” under the Drugs & Cosmetics Act, 1940 and Rules. The practical point for a C&F applicant is simple: your licensing, storage and distribution obligations are determined by the medicines you handle and the applicable rules—not by a marketing label alone.
This page therefore uses “generic medicine companies” in the broader commercial sense of pharmaceutical companies with significant generic/formulation portfolios. It does not imply that every product handled will be an unbranded generic.
4. Are C&F agent vacancies available across India?
There is no reliable master list proving that all major pharma companies are appointing C&F agents in every state at the same time. Vacancies arise when a company opens a new depot, replaces an existing agent, restructures a state, adds a business division, changes its distribution model, expands institutional business or needs stronger service capability.
Karnataka Antibiotics & Pharmaceuticals Limited (KAPL), a Government of India enterprise, published a 2026 notice for appointment of C&F agencies across India. Its public notice specifically asked for essential infrastructure, warehousing facilities, office setup, trained manpower, transportation arrangements and applicable statutory registrations/licences.
The cited KAPL tender was dated 26 June 2026 and its submission deadline has passed, so it is used here as a recent verified example of selection requirements—not as a current vacancy. View KAPL's official notice →
How to verify a vacancy before spending money
- Identify the exact company, division and geography. “Pan India C&F” is too vague for due diligence.
- Check the company's official website / tender / procurement / contact route. Search the legal company name, not only the brand name.
- Verify the person independently. Call a corporate number obtained independently and ask whether the employee/vendor process is genuine.
- Ask why the vacancy exists. New depot, replacement, additional division or territory restructuring should have a clear business reason.
- Request written scope before payment. State, products, expected throughput, services, warehouse requirement and commercial structure should be clear.
- Never confuse a third-party lead with a company appointment. A lead can start a conversation; only the principal company can appoint you.
5. Top 20 generic & formulation pharma companies to research for C&F opportunities in India
If your goal is to build a serious pharma C&F pipeline, start with companies that have meaningful India formulation, generic, branded-generic or domestic therapy presence. The 20 names below are an editorial research shortlist built around current India-market relevance, product breadth, formulation/generic presence and official company information.
India's largest pharmaceutical company by domestic market presence, with a wide branded-generics, specialty and formulation portfolio across chronic and acute therapies.
A major domestic formulations player with broad acute and chronic portfolios, large prescription reach and strong India distribution infrastructure.
Large Indian pharma company with 1,500+ products and strong presence in respiratory, generics, anti-infectives, chronic therapies and other formulations.
Strong India-formulations business across anti-infectives, gastroenterology, cardiology, neurology, diabetology and multiple other therapy areas.
Formulation-focused multinational with a broad product basket and presence across more than 85 countries, including significant India operations.
Leading Indian formulation company with particularly strong chronic-therapy presence across cardiovascular, CNS, gastro and related segments.
Diversified pharmaceutical company spanning global generics, complex formulations, branded products, specialty segments and a strong India business.
Large Ahmedabad-headquartered lifesciences group with formulations, APIs, vaccines, biosimilars and complex-product capabilities.
Major generics company spanning branded and unbranded generics, APIs/services, innovative medicines and consumer-health businesses.
Vertically integrated pharma company with broad formulations across anti-infectives, TB, respiratory, cardiovascular, diabetes and other major therapies.
One of India's major global generic and API players, with very large formulation manufacturing capabilities and presence across 150+ markets.
Global pharmaceutical company combining accessible formulations with a strong therapy focus in respiratory, dermatology and oncology.
Large domestic formulations player; its official site cites a strong current position in the Indian Pharma Market and a broad therapy portfolio.
Specialty pharmaceutical company with branded generics in India and emerging markets plus a separate generics business in the US.
Vertically integrated pharmaceutical company operating across India formulations, international generics and active pharmaceutical ingredients.
Established Indian formulations and API company with domestic products, international presence and a broad therapy footprint.
Domestic and international formulations company with 350+ brands across 20 key therapy areas and extensive pharmacy reach in India.
Prominent India pharma company with major strength in oral anti-diabetes and cardiac therapies, along with generics, biosimilars and other businesses.
Broad formulations company with strong domestic roots, multiple therapy segments and a sizeable manufacturing network across India.
Fast-growing domestic branded-formulations company with a strong chronic and specialist focus, including cardio-metabolic and other specialist therapies.
Do not send the same message to all 20 companies. First shortlist 5-7 names whose product mix, state network and operating requirements fit your warehouse, licences and team. Then verify whether that company uses an external C&F/CFA model in your geography and whether a real requirement exists.
Research basis: current official company websites, current Indian pharma-industry presence and 2025-26 industry/company disclosures. Inclusion here is for applicant research only.
6. Who is actually suitable for a pharma C&F agency?
Money alone is not enough. A principal usually needs an operator who can protect stock, comply with licences, dispatch accurately and maintain data. The following is a practical DistributorsBazar applicant-readiness framework, not any pharmaceutical company's internal score.
Drug licences & compliance readiness
Warehouse & storage capability
Pharma / distribution experience
Trained manpower & supervision
IT / batch / inventory controls
Financial strength & buffer
Transport / dispatch / SLA capability
Strong applicant profiles
- Existing pharmaceutical C&F agent, stockist or super stockist with clean compliance.
- Pharma distributor upgrading into a depot-level service model.
- Healthcare logistics operator with compliant pharma storage capability.
- Experienced warehouse operator willing to build the drug-licence, competent-person and quality systems required.
- Professionally funded new entrant with a qualified pharma operations team—not just an empty godown and investment capacity.
7. Pharma C&F licences and statutory compliance: what may be required?
Drug sale, stocking and distribution are regulated. A March 2026 Government of India reply states that manufacture, sale and distribution of drugs are regulated under the Drugs & Cosmetics Act and Rules through licensing and inspection by the relevant State Licensing Authorities. The exact licence set depends on the products and what your premises will legally do.
| Licence / compliance item | What the central Drugs Rules indicate | Applicant takeaway |
|---|---|---|
| Form 20B | Wholesale sale/stock/distribution of drugs other than Schedules C, C(1) and X | Common wholesale licence category; confirm applicability with State Licensing Authority. |
| Form 21B | Wholesale drugs in Schedules C and C(1), excluding Schedule X | Relevant when the product portfolio includes applicable Schedule C/C(1) items. |
| Form 20G | Wholesale drugs specified in Schedule X | Only relevant if such products are in scope; additional controls apply. |
| GST / entity / local registrations | Depends on legal/tax and local business position | Principal companies normally expect a compliant registered business; confirm current tax requirements professionally. |
| Premises & product conditions | Licensing is premises/product specific and storage conditions remain binding | Do not shift stock or add product categories casually; validate licence and SOP impact first. |
The famous “10 square metre” rule—what it really means
CDSCO's consolidated Drugs Rules text states that, for a wholesale licence in Form 20B or Form 21B or both, the licensing authority must be satisfied that the premises are at least 10 square metres and are in the charge of a competent person. Where retail Forms 20/21 and wholesale Forms 20B/21B are sought together, the Rules refer to at least 15 square metres.
Do not confuse statutory minimum premises with commercial C&F capacity. A serious state-level C&F may need hundreds or thousands of square feet—or much more—depending on monthly throughput, pallet positions, divisions, cold-chain needs, quarantine/returns space and the principal's audit standard.
Who can be the “competent person”?
The central Rule 64 text currently available through CDSCO lists, for 20B/21B wholesale licensing, a competent person who may be a registered pharmacist, or a person with matriculation/equivalent plus four years' experience dealing with sale of drugs, or a recognised-university degree plus one year's experience dealing with drugs. State licensing practice and later amendments should always be checked before applying; do not hire staff only from a blog description.
Regulatory references: CDSCO Drugs Rules consolidated text and CDSCO latest Gazette notifications.
8. Pharma C&F warehouse blueprint: design for control, not just square feet
A generic-medicine C&F warehouse should be designed around product flow and risk. The correct size is derived from peak stock, pallet/carton density, order frequency, returns volume, product conditions and company SOPs.
Unload, count, inspect, document transporter damage and segregate product before put-away.
Batch-wise mapped storage, racks/pallets, labelled locations, controlled movement and cycle counts.
Physically or system-controlled area for damaged, suspect, recalled or non-saleable material.
Separate workflow for market returns, near-expiry, expired stock, credit-note documents and disposal instructions.
Only if the allotted products require it: appropriate refrigeration/air-conditioning, monitoring, alarms and backup as specified.
Pick, verify, pack, invoice and stage by route/customer without mixing batches or orders.
Warehouse questions a principal's audit team may care about
- Can batches and expiry dates be traced from receipt to dispatch?
- Are temperature and humidity controls adequate for products handled?
- Is there backup power for required cold/controlled storage?
- Are rejected, returned and recalled goods prevented from accidental dispatch?
- Are pest-control, cleaning and sanitation records maintained?
- Are racks/pallets, fire systems, CCTV/security and access controls adequate?
- Can the facility absorb seasonal or launch-period peak inventory?
- Can the team complete a recall/stock-trace exercise quickly and accurately?
9. Investment for a generic-medicine C&F agency: use the correct model
A single “minimum investment ₹20 lakh” type figure is not reliable for this business. In a pure C&F arrangement, the principal may own the inventory while the agent invests in infrastructure and operations. In another agreement, the agent may have deposits, guarantees, transport obligations or even working-capital exposure. Your contract defines your real capital requirement.
Add inventory working capital only if the actual commercial structure requires you to fund/purchase stock.
| Capital bucket | What to budget | Ask the principal before fixing amount |
|---|---|---|
| Warehouse | Deposit, rent, flooring, racks, pallets, partitions | Minimum usable area, location, pallet positions, audit specs |
| Storage systems | AC/cold room if needed, data loggers, backup power | Exact temperature-sensitive portfolio and validation standard |
| IT & controls | Computers, scanners, printers, internet, WMS/DMS support | Who provides software and hardware; integration responsibility |
| Manpower | Manager, competent person, billing, store staff, loaders, security | Minimum headcount, shifts, SLA and training requirements |
| Transport | Owned/leased vehicles or transporter contracts | Delivery scope, radius, frequency and reimbursement terms |
| Security / BG | Deposit or bank guarantee if required | Amount, validity, invocation conditions and release terms |
| Operating buffer | 3-6 months of expected fixed costs as your own stress test | Payment cycle, reimbursement cycle and ramp-up period |
A better question than “minimum investment?”
Ask: “At the expected monthly throughput, how much infrastructure and operating cash must I fund until all service fees and reimbursements are received?” That question reveals the real capital burden.
10. How does a pharma C&F agent earn money?
A C&F agent's earning should not automatically be called a “distributor margin”. Depending on the agreement, compensation can be a fixed monthly service fee, turnover-linked service charge, per-case/per-invoice handling fee, logistics reimbursement, KPI-linked incentive or a hybrid structure.
Predictable service income; profitability depends on controlling fixed warehouse/manpower cost.
Revenue moves with dispatch value, cases, invoices or another agreed measure.
Fixed support + variable handling + approved reimbursements / performance components.
Before celebrating a high fee, check whether the contract makes you responsible for transport, manpower, damage, shortage, cold-chain power, insurance deductible, stock loss, late dispatch penalties or unrecovered customer exposure. The liability clause can matter more than the headline commission.
11. The operational KPIs that separate a professional C&F from a godown
Large principals need measurable service. Build your operation so you can report and improve these metrics:
System stock vs physical stock.
What proportion of authorised orders are fulfilled.
Order cut-off to invoice/dispatch.
Near-expiry value and ageing control.
Loss generated during custody/handling.
How fast a batch can be located for recall.
Excursions and corrective action where relevant.
Returns/damage/credit-note cases pending.
12. Documents to prepare before approaching a pharma company
Do not send only your name, phone number and investment. Build an appointment dossier showing that your business can survive a company audit.
| Dossier section | Keep ready |
|---|---|
| Business identity | Entity registration, PAN, GST as applicable, authorised signatory details, Udyam if applicable. |
| Drug compliance | Current drug licences relevant to products/premises, competent-person details and inspection/compliance history. |
| Financial strength | Audited financials/ITRs, bank statements or banker certificate, funding/BG capability where required. |
| Warehouse | Ownership/lease proof, address, carpet/usable area, layout, photographs, loading access, fire/security systems. |
| Temperature control | AC/cold-room details if relevant, monitoring system, backup power and maintenance/validation records. |
| Team | Organisation chart, experienced manager, competent person, billing/store/dispatch manpower. |
| Transport & network | Vehicles/transporter arrangements, serviceable districts, dispatch frequencies and POD process. |
| Technology | ERP/WMS/DMS capability, batch/expiry controls, barcode/scanning, internet redundancy, backup process. |
| Experience | Current/prior principals, monthly dispatch scale, references, audit record and key service achievements. |
13. How to apply for generic-medicine C&F agency opportunities
State, depot city and service districts. A company needs to know where your warehouse is and what area you can service.
C&F/CFA, super stockist, stockist or PCD franchise. Do not submit the same generic enquiry for every model.
Identify which drug licences, competent-person arrangements and warehouse upgrades would be needed for the proposed portfolio.
One strong PDF/profile with area, licence, warehouse, experience, manpower, IT, financial capacity and transport details is better than repeated WhatsApp messages.
Prioritise companies whose product categories and depot strategy fit your facility and geography.
Use verified company contacts, tenders, vendor portals or independently authenticated employees.
A genuine process may include document review, financial checks, warehouse inspection, licence verification, reference checks, capacity discussions and negotiation.
Understand stock ownership, shortage liability, insurance, security/BG, service fee, GST treatment, transport, claims, audit rights and exit settlement before spending heavily.
A 90-day applicant preparation plan — not an approval promise
Territory, model, licence gap and company shortlist.
Warehouse audit, layout, compliance files and financial dossier.
IT/manpower/transport planning and verified outreach.
Respond to genuine evaluations and refine facility/commercial model.
A company may take less or much more time—or may have no vacancy. This timeline is only for making your business appointment-ready.
14. How to choose the right generic-pharma C&F opportunity
The biggest brand is not automatically the best contract. Score the opportunity on the operating model.
Stable monthly dispatch, product mix, seasonality.
Fixed vs variable, escalation, reimbursement and payment cycle.
Shortage, damage, expiry, customer credit, insurance and penalties.
How much capex is company-specific and difficult to reuse?
Notice, stock handover, claims, deposit/BG release.
Can your licence and facility legally handle the proposed portfolio?
15. Before signing a pharma C&F agreement: 24 questions to ask
- Which state, districts and divisions are covered?
- Is appointment exclusive? For which products/channels?
- Who owns the inventory at every stage?
- What is the service-fee formula?
- Is there a minimum guaranteed fee/throughput?
- How and when can the fee be revised?
- What expenses are reimbursed?
- What deposit or bank guarantee is required?
- What is the payment/reimbursement cycle?
- Who bears customer default/receivable risk?
- Can another C&F/depot be opened in the territory?
- What happens if volume is far below projection?
- What warehouse, cold-chain and security standards apply?
- Who pays for IT hardware/software and upgrades?
- What dispatch SLA and penalties apply?
- Who is liable for transit loss?
- Who is liable for warehouse shortage/damage?
- How are expiry, recalls and market returns handled?
- Who insures principal-owned inventory and what exclusions apply?
- What audit rights does the principal have?
- Can you handle other companies from the same premises?
- What notice period applies on termination?
- How are pending claims and stock reconciled on exit?
- When and how is the deposit/BG released?
16. Fraud protection: do not pay for a “pharma C&F slot” without verification
Pharma is a regulated industry, but fake appointment letters and unofficial agency offers can still appear. A polished PDF, company logo or website domain containing the brand name is not enough.
- Guaranteed appointment before warehouse/licence/business evaluation.
- Personal UPI/bank account for “territory booking”.
- Pressure to pay within a few hours to stop another applicant.
- Free-email address presented as the company's official procurement desk.
- No clear legal entity, GST invoice, agreement or corporate verification.
- Large stock-purchase demand described as a pure C&F appointment without clear contract logic.
Before any payment, verify all five
- Person: employee/authorised vendor identity independently.
- Entity: exact legal principal/company.
- Bank: beneficiary matches written commercial documentation.
- Scope: geography, services, products and vacancy reason.
- Agreement: fee, liability, refund/settlement, security and exit.
17. Can a first-time entrepreneur become a pharma C&F agent?
Possible does not mean easy. A first-time entrepreneur has to compensate for lack of operating history with stronger systems, experienced hires, financial discipline and a compliant facility. If you have only capital and no pharma operations team, a smaller distributorship/stockist model may sometimes be a more realistic entry path than a large state-level C&F responsibility.
| Your profile | Natural strength | Main gap before C&F |
|---|---|---|
| Existing pharma C&F / stockist | Licences, people, market systems | Capacity and principal conflict check |
| Logistics / warehouse operator | Facility/process discipline | Drug compliance and pharma quality systems |
| Pharma sales professional | Industry knowledge and contacts | Warehouse, capital and operations management |
| New investor | Can build clean systems from start | Experienced team, licences and execution proof |
18. State-wise opportunity strategy: where should you apply?
Do not chase every state. A C&F depot works best where your facility and transport network create a service advantage. Build a state case around:
- Proximity to major stockist/distributor clusters.
- Road connectivity and courier/transport availability.
- Affordable but compliant warehouse locations.
- Availability of trained pharma warehouse/billing staff.
- Ability to service district headquarters within the principal's expected TAT.
- Power reliability for any temperature-controlled products.
- Current gap in the principal's depot/C&F network—not merely population size.
For wider cross-industry research on the C&F model, you can also read C&F business opportunities in India before deciding whether pharma, FMCG or another sector fits your infrastructure and risk appetite better.
If you want DistributorsBazar to help you explore suitable C&F, super-stockist or distributorship opportunities, share your city/state, current business, pharma experience, warehouse size/location, drug-licence status and investment/operating capacity. We can use that profile to help you research relevant options. Final vacancy, selection and appointment remain with the respective company.
Frequently asked questions about pharma & generic-medicine C&F agencies
How can I become a C&F agent for a generic medicine company?
Choose a state/depot location, prepare compliant warehousing and drug-licence capability, build a professional business dossier, identify genuine company requirements, approach through verified official channels and complete the principal's financial/site/commercial evaluation.
What is the investment required for a pharma C&F agency?
There is no universal fixed amount. In a pure C&F model, principal-owned inventory may reduce stock funding, while warehouse setup, licences, staff, IT, transport, deposit/BG and operating buffer can dominate your investment. Calculate from the actual contract.
What commission or margin does a pharma C&F agent get?
C&F compensation varies by agreement and may use fixed fees, handling charges, turnover-linked service fees, reimbursements or hybrid structures. Do not rely on one online percentage as an industry guarantee.
Is a wholesale drug licence required?
If your premises will sell, stock or distribute drugs by wholesale, appropriate licences under the Drugs Rules can apply. Forms 20B, 21B and 20G cover different drug categories. Confirm your exact product/operation with the State Licensing Authority before starting.
Is a registered pharmacist compulsory for every wholesale C&F licence?
The central Rule 64 text for 20B/21B also describes certain experience/education routes for the competent person in addition to a registered pharmacist. Because state licensing practice and rules can be updated, verify current eligibility with your State Licensing Authority.
What is the minimum warehouse size for a pharma C&F agent?
The central Rules refer to a 10-square-metre minimum for premises seeking Form 20B/21B wholesale licensing, but that is only a regulatory floor for those licences—not a practical C&F warehouse recommendation. The principal may require far more space based on throughput and audit standards.
Is cold storage compulsory for generic medicines?
No single cold-storage rule applies to every generic medicine. Storage must follow the conditions applicable to each product and the principal's SOP. If your portfolio contains temperature-sensitive products, proper controlled storage, monitoring and backup systems may be required.
Can a C&F agent handle more than one pharmaceutical company?
Potentially yes, but only if each agreement permits it, licences and premises are appropriate, stock/records are properly controlled and there is no contractual conflict or exclusivity restriction. Ask every principal in writing.
Is C&F more profitable than pharma distributorship?
They are different models. C&F may use less inventory capital in a principal-owned-stock structure but carries warehouse/service liabilities. Distribution may offer trade margin but uses more inventory and receivable capital. Compare return on capital and risk, not just revenue.
Can a first-time entrepreneur apply?
Yes, you can approach companies, but a major pharma C&F role generally rewards proven compliance and operations capability. A new entrant should hire experienced pharma operations staff and build a compliant facility before expecting serious consideration.
Which generic medicine companies are appointing C&F agents right now?
Vacancies change by state, division and time, and there is no trustworthy universal live list. Verify each company individually through official channels. Recent public tender notices can demonstrate real demand, but an expired tender must not be presented as a current opening.
What should I send in my first C&F enquiry?
Send state/city, exact warehouse location and usable area, drug-licence status, current business/principals, pharma experience, team strength, transport capability, IT systems and financial/BG capacity. This is much more useful than sending only your mobile number and budget.
Final 10-point go / no-go checklist
- I know whether I want C&F, super stockist, distributor or PCD.
- I have a specific state/depot geography.
- I understand which drug licences my proposed portfolio needs.
- My warehouse is sized for commercial throughput, not merely statutory minimum area.
- I have a competent pharma operations team.
- I know whether inventory is company-owned or funded by me.
- I have mapped service fee, reimbursements and all operating costs.
- I understand stock loss, expiry, recall, transit and insurance liabilities.
- I have independently verified the vacancy and the person offering it.
- I will commit money only after written scope and agreement review.
- Government of India / Department of Pharmaceuticals — 2026 pharmaceutical industry scale and generic-supply data
- Government of India — March 2026 reply on generic medicines and drug regulation
- Competition Commission of India — pharmaceutical distribution / C&F supply-chain role
- Karnataka Antibiotics & Pharmaceuticals Ltd — 2026 C&F appointment notice example
- CDSCO — consolidated Drugs Rules text (Forms 20B, 21B, 20G; Rule 64)
- CDSCO — current Gazette notifications / amendments
Vacancy, fees, BG/security, territory, warehouse standards and product scope are dynamic commercial terms. Verify them from the current principal-company offer and the relevant licensing authority before investment.
